Table 2.
Body weight loss with glucagon-like peptide 1 receptor agonists versus placebo
| Trial name | GLP-1RA | Body weight loss vs placebo (95% CI), kg | Median follow-up duration, years | References |
|---|---|---|---|---|
| LEADER | Liraglutide | 2.3 (− 2.54, − 1.99) | 3.8 | [6] |
| SUSTAIN-6 | Semaglutide 0.5 mg | 2.9 | 2.1 | [21] |
| Semaglutide 1.0 mg | 4.3 | |||
| HARMONY | Albiglutide | 1.8 (1.7, 2.0) | 1.3 | [7] |
| EXSCEL | Exenatide | 1.27 (− 1.4, − 1.13) | 3.2 | [20] |
| ELIXA | Lixisenatide | 0.7 (− 0.9, − 0.5) | 2.1 | [22] |
| REWIND | Dulaglutide | 1.46 (1.25, 1.67) | 5.4 | [5] |
CI confidence interval, GLP-1RA glucagon-like peptide 1 receptor agonist